AKCA Akcea Therapeutics Inc.

19.57
-0.57  -3%
Previous Close 20.14
Open 19.96
Price To Book 4.94
Market Cap 1,820,643,794
Shares 93,032,386
Volume 367,397
Short Ratio
Av. Daily Volume 282,938
Stock charts supplied by TradingView

NewsSee all news

  1. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  2. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  3. Akcea Announces CEO Transition and Elects Two New Board Members

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  4. Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients

  5. Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Pilot study data due mid-2019.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx
Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus
Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
Phase 3 trial to be initiated 2H 2019.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 3 data met primary endpoint - August 6, 2019.
Volanesorsen
Familial partial lipodystrophy (FPL)
Phase 1 data presented at HFSA September 13, 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis

Latest News

  1. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx

    Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that the companies have entered into a worldwide exclusive

  2. Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)

    BOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) and Pfizer Inc. (NYSE:PFE), today announced that

  3. Akcea Announces CEO Transition and Elects Two New Board Members

    BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt,

  4. Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting

    Data show >90% knockdown of TTR following administration in healthy volunteers Positive safety and tolerability profile for LICA platform-based therapy Phase 3 program on track to start later this year in patients

  5. Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

    Multiple presentations on the long-term efficacy and safety of TEGSEDI® (inotersen) in patients with polyneuropathy caused by hATTR Amyloidosis Topline data results to be presented from the Phase 1 study of